Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

PHG

Koninklijke Philips Stock in Brief

It's been a great afternoon session for Koninklijke Philips investors, who saw their shares rise 2.7% to a price of $27.95 per share. At these higher prices, is the company still fairly valued? If you are thinking about investing, make sure to check the company's fundamentals before making a decision.

Koninklijke Philips's Valuation Is in Line With Its Sector Averages:

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 22.94 and an average price to book (P/B) ratio of 3.19. In contrast, Koninklijke Philips has a trailing 12 month P/E ratio of 147.1 and a P/B ratio of 2.56.

Koninklijke Philips has moved 0.5% over the last year compared to 18.5% for the S&P 500 — a difference of -18.0%. Koninklijke Philips has a 52 week high of $29.29 and a 52 week low of $21.48.

The Business Is Unprofitable and Its Balance Sheet Is Highly Leveraged:

2019 2020 2021 2022 2023 2024
Revenue (M) $17,147 $17,313 $17,156 $17,827 $18,169 $18,021
Gross Margins 46% 45% 42% 40% 41% 43%
Net Margins 7% 7% 19% -9% -3% -4%
Net Income (M) $1,173 $1,195 $3,323 -$1,605 -$463 -$698
Net Interest Expense (M) $196 $173 $159 $235 $277 $288
Depreciation & Amort. (M) $1,343 $1,462 $1,323 $1,602 $1,261 $1,390
Diluted Shares (M) 891 905 870 881 906 925
Earnings Per Share $1.25 $1.29 $3.5 -$1.69 -$0.49 -$0.75
EPS Growth n/a 3.2% 171.32% -148.29% 71.01% -53.06%
Total Debt (M) $4,939 $5,705 $6,473 $7,270 $7,035 $7,113
Net Debt / EBITDA 1.3 0.91 2.22 83.53 4.51 2.46
Current Ratio 1.36 1.45 1.39 1.29 1.2 1.23

Koninklijke Philips has slimmer gross margins than its peers, declining EPS growth, and a highly leveraged balance sheet. Koninklijke Philips has just enough current assets to cover current liabilities, as shown by its current ratio of 1.23.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS